The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors?

REYNOLDS, Gavin (2024). The trace amine-associated receptor 1 agonists – non-dopaminergic antipsychotics or covert modulators of D2 receptors? Journal of Psychopharmacology, 38 (6), 503-506.

[img]
Preview
PDF
Reynolds-TheTraceAmineAssociated( VoR ).pdf - Published Version
Creative Commons Attribution Non-commercial.

Download (149kB) | Preview
Official URL: http://dx.doi.org/10.1177/02698811241249415
Open Access URL: https://journals.sagepub.com/doi/pdf/10.1177/02698... (Published version)
Link to published version:: https://doi.org/10.1177/02698811241249415

Abstract

A major effort of the pharmaceutical industry has been to identify and market drug treatments that are effective in ameliorating the symptoms of psychotic illness but without the limitations of the current treatments acting at dopamine D2 receptors. These limitations include the induction of a range of adverse effects, the inadequate treatment response of a substantial proportion of people with schizophrenia, and the generally poor response to negative and cognitive features of the disease. Recently introduced drug treatments have gone some way to avoiding the first of these, with a reduced propensity for weight gain, cardiovascular risk and extrapyramidal motor effects. Despite claims of some small improvements in negative symptoms, these drugs have not demonstrated substantial increases in efficacy. Of the drugs currently in development as antipsychotic agents, several are misleadingly described as having novel ‘non-dopaminergic’ mechanisms that may offer improvements in addressing the limitations of adverse effects and efficacy. It will be argued, using the trace amine-associated receptor 1 agonist as an example, that several of these new drugs still act primarily through modulation of dopaminergic neurotransmission and, in not addressing the primary pathology of schizophrenia, are therefore unlikely to have the much-needed improvements in efficacy required to address the unmet need associated with resistance to current treatments.

Item Type: Article
Uncontrolled Keywords: 11 Medical and Health Sciences; 17 Psychology and Cognitive Sciences; Psychiatry; 32 Biomedical and clinical sciences; 42 Health sciences
Identification Number: https://doi.org/10.1177/02698811241249415
Page Range: 503-506
SWORD Depositor: Symplectic Elements
Depositing User: Symplectic Elements
Date Deposited: 01 May 2024 12:25
Last Modified: 24 Jun 2024 11:30
URI: https://shura.shu.ac.uk/id/eprint/33656

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics